CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 983 enrolled
Drug / intervention
ENG 120 µg + EE 15 µg intravaginal ring +1 moredrug
Likely dose
ENG 120 µg + EE 15 µg intravaginal ringfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01277211
NCT01277211Phase 3Completed
CompareCT.gov

A Randomized, Open-Label, Controlled, Multi-Center Trial to Evaluate the Contraceptive Efficacy, Cycle Control, Safety and Acceptability of NuvaRing® (SCH 900702) in Chinese Women

Organon and Co·interventional·Posted Jan 14, 2011·Updated Jun 20, 2024

In Brief

A Phase 3 clinical trial evaluating ENG 120 µg + EE 15 µg intravaginal ring and DRSP 3 mg + EE 30 µg for Contraception. Completed, enrolled 983 participants.

Detailed Summary

This is a study to assess the effectiveness of NuvaRing® (SCH 900702) for the prevention of pregnancy in fertile Chinese women. The acceptability and safety of NuvaRing® will also be assessed and compared with that of Yasmin.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 14, 2011
Enrollment StartSep 19, 2011
Primary CompletionSep 18, 2013
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 15.5 years ago

Interventions

ENG 120 µg + EE 15 µg intravaginal ringdrug

13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.

DRSP 3 mg + EE 30 µgdrug

13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.